Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.61 |
| ▸ | IGF1R | P08069 | 5/20 | 0.61 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.58 |
| ▸ | CCND3 | P30281 | 4/20 | 0.53 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.53 |
| ▸ | CDK4 | P11802 | 4/20 | 0.53 |
| ▸ | CCND1 | P24385 | 4/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28718949 | 1.00 | CDK2 (0.61) | CDK2IGF1RMAP4K1CCND3CDK6 | |
| SCHEMBL27658496 | 0.90 | CDK2 (0.73) | CDK2IGF1RCDK4JAK2PLK4 | |
| SCHEMBL28718946 | 0.90 | CDK2 (0.60) | CDK2IGF1RMAP4K1CCND3CDK6 | |
| SCHEMBL30011867 | 0.90 | CDK2 (0.60) | CDK2IGF1RMAP4K1CCND3CDK6 | |
| SCHEMBL30011362 | 0.88 | IRAK4 (0.60) | CDK2IGF1RCCND3CDK6CDK4 | |
| SCHEMBL28715558 | 0.88 | IRAK4 (0.60) | CDK2IGF1RCCND3CDK6CDK4 | |
| SCHEMBL22876438 | 0.88 | CDK2 (0.63) | CDK2IGF1RCCND3CDK6CDK4 | |
| SCHEMBL30010854 | 0.88 | CDK2 (0.63) | CDK2IGF1RCCND3CDK6CDK4 | |
| SCHEMBL22876093 | 0.86 | CDK2 (0.60) | CDK2IGF1RCCND3CDK6CDK4 | |
| SCHEMBL30967325 | 0.86 | CDK2 (0.60) | CDK2IGF1RCCND3CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-08-26 | — | — | US | disclosed |
| CN-114269742-B | Derivatives of 4- (imidazo [1,2-a ] pyridin-3-yl) -N- (pyridinyl) pyrimidin-2-amine as therapeutic agents | 常州千红生化制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20220259203-A1 | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2022-08-18 | — | — | US | disclosed |
| EP-3997088-A1 | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS | Aucentra Therapeutics Pty Ltd (AU) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259203-A1 | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS | FLT3, CDK2, CDK4 | CDK2 2/4885IGF1R 310/4885MAP4K1 89/4885 |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | FLT3, CDK2, CDK4 | CDK2 2/4885IGF1R 296/4885MAP4K1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.